首页 > 资讯 > DeepHealth在#ECR2025上推出了新的人工智能驱动的放射信息学和人群筛查解决方案

DeepHealth在#ECR2025上推出了新的人工智能驱动的放射信息学和人群筛查解决方案

泰然健康网
2025-06-10 03:48

At ECR 2025, DeepHealth will introduce new AI-powered radiology informatics and cancer screening solutions enabled by DeepHealth OS, its pioneering cloud-native operating system, to address clinical and operational challenges.

在ECR 2025上，DeepHealth 将推出由其开创性的云原生操作系统 DeepHealth OS 支持的全新 AI 驱动的放射信息学和癌症筛查解决方案，以应对临床和运营挑战。

DeepHealth aims to bring to European customers its

DeepHealth 旨在为欧洲客户带来其

to redefine the traditional Picture Archiving and Communication System (PACS) with a unified workspace tailored for modern radiology, and

重新定义传统的图像存档与通信系统 (PACS)，打造一个专为现代放射学设计的统一工作区，并且

, an AI-powered end-to-end diagnostic SaaS solution for mammography, further embedding AI-based detection and diagnosis in interpretive workflows.

，一个用于乳腺X线摄影的端到端人工智能诊断SaaS解决方案，进一步将基于人工智能的检测和诊断嵌入到解释工作流程中。

DeepHealth will also showcase updates to its broader population health portfolio of clinical AI solutions supporting lung, prostate, and brain health.

DeepHealth 还将展示其支持肺部、前列腺和大脑健康的更广泛人群健康临床 AI 解决方案组合的更新。

To extend and scale these solutions, DeepHealth leverages strategic collaborations with leading industry players, such as enterprise imaging solutions provider TeraRecon and AI infrastructure company CARPL.ai.

为了扩展和规模化这些解决方案，DeepHealth 与行业领先的企业建立了战略合作伙伴关系，例如企业影像解决方案提供商 TeraRecon 和 AI 基础设施公司 CARPL.ai。

VIENNA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), will introduce next-generation AI-powered radiology informatics and population screening solutions at the European Congress of Radiology (ECR) 2025 in Vienna.

维也纳，2025年2月26日（环球新闻社）——DeepHealth, Inc. 是一家全球领先的AI驱动健康信息学公司，也是RadNet, Inc.（纳斯达克股票代码：RDNT）的全资子公司，将在2025年维也纳欧洲放射学大会（ECR）上推出下一代AI驱动的放射信息学和人群筛查解决方案。

With the aim of empowering breakthroughs in care enabled by imaging, DeepHealth’s suite of solutions addresses critical clinical and operational challenges experienced by healthcare providers around the world. DeepHealth’s solutions are powered by DeepHealth OS, a secure, scalable, and cloud-native operating system that integrates data across various solutions and enables interoperability with broader healthcare IT ecosystems.

为了推动影像赋能的护理突破，DeepHealth 的解决方案套件应对了全球医疗保健提供者面临的重大临床和运营挑战。DeepHealth 的解决方案由 DeepHealth OS 提供支持，这是一个安全、可扩展且基于云原生的操作系统，能够跨各种解决方案整合数据，并实现与更广泛的医疗 IT 生态系统的互操作性。

Moreover, to enable AI adoption at scale, DeepHealth has established strategic collaborations enabling integrated solutions with ecosystem industry leaders..

此外，为了实现大规模的人工智能应用，DeepHealth 已经与生态系统行业的领导者建立了战略合作伙伴关系，以提供集成解决方案。

“At DeepHealth, we are harnessing the transformative power of AI to create cutting-edge solutions that are deeply rooted in real-world clinical needs,” said Kees Wesdorp, PhD, President and CEO of RadNet’s Digital Health division. “We believe that AI adoption at scale in radiology can only be achieved by embedding AI into and unifying data across clinical and operational workflows to empower radiologists and care teams that today are having to rely on disconnected devices and disparate data sources.

“在DeepHealth，我们正在利用人工智能的变革力量，开发深植于现实临床需求的前沿解决方案，”RadNet数字健康部门总裁兼首席执行官Kees Wesdorp博士表示。“我们认为，只有将人工智能嵌入到临床和操作工作流程中，并统一数据，才能实现放射学领域的人工智能规模化应用，从而赋能放射科医生和护理团队，他们如今不得不依赖互不相连的设备和分散的数据来源。”

At ECR 2025, we are excited to showcase our next-generation radiology informatics and population screening solutions designed to enhance operational efficiency, clinical confidence, and care delivery across the radiology continuum.”.

在ECR 2025上，我们很高兴展示我们下一代的放射信息学和人群筛查解决方案，这些方案旨在提高整个放射学领域的运营效率、临床信心和护理质量。

Streamlining workflows with next-generation radiology informatics solutions

利用下一代放射学信息学解决方案简化工作流程

DeepHealth aims to bring to European customers its latest innovations that harness the power of AI to streamline operations, support higher volumes of patients, and assist radiologists and care teams in diagnosing patients faster and with greater accuracy.

DeepHealth 旨在为其欧洲客户带来最新的创新成果，利用人工智能的力量简化操作流程、支持更多的患者量，并协助放射科医生和护理团队更快、更准确地诊断患者。

At ECR 2025, DeepHealth will showcase

在ECR 2025上，DeepHealth将展示

Diagnostic Suite™,

诊断套件™，

which harnesses the cloud-native capabilities of DeepHealth OS to set a new benchmark in medical imaging technology and the traditional Picture Archiving and Communication System (PACS). Diagnostic Suite delivers a unified AI-powered interpretive experience that is intended to seamlessly integrate with or replace existing RIS/PACS systems, bringing advanced capabilities to meet the evolving demands of radiologists.

它利用DeepHealth OS的云原生能力，在医学影像技术以及传统的图像存档和通信系统（PACS）中树立了新的标杆。Diagnostic Suite提供了一个统一的、由人工智能驱动的解读体验，旨在无缝集成或替代现有的RIS/PACS系统，为放射科医生带来满足不断变化需求的先进功能。

A unified application, the diagnostic workspace brings together worklist, patient brief, reporting, and high-speed streaming viewer technologies with advanced visualization and AI orchestration capabilities. Diagnostic Suite is cloud-native, enabling high reliability and scalability to practices of all sizes and scale..

一个统一的应用程序，诊断工作区将工作列表、患者简介、报告和高速流媒体查看器技术与高级可视化和人工智能编排功能结合在一起。诊断套件是云原生的，能够为各种规模的实践提供高可靠性和可扩展性。

DeepHealth is also announcing upcoming updates to

DeepHealth 还宣布了即将到来的更新

, a comprehensive suite of advanced tools designed to optimize breast cancer screening and diagnosis for more efficient workflows, which will support 2D mammograms, further improving local workflow integration. DeepHealth’s 3D solution is compatible with leading OEMs and integrates seamlessly with radiologist worklists and reporting tools.

，一套全面的先进工具套件，旨在优化乳腺癌筛查和诊断，以实现更高效的工作流程，该套件将支持2D乳房X光片，进一步改善本地工作流程整合。DeepHealth的3D解决方案与领先的原始设备制造商兼容，并能无缝集成到放射科医生的工作列表和报告工具中。

It features clinical AI detection capabilities that automatically localize lesions and assess suspicion levels across diverse populations and dense breast tissue, enabling a 21% increase in cancer detection rate..

它具有临床AI检测功能，可自动定位病灶并评估不同人群和致密乳腺组织的可疑程度，从而使癌症检出率提高21%。

The updates will incorporate already CE-marked 2D technology to assist in the primary read and fulfill the second reader role in mammography double reading workflows.

更新将整合已获得CE标志的2D技术，以协助初步读取，并在乳腺X线摄影双读工作流程中履行第二读取者的角色。

State-of-the-art clinical AI solutions for lung, prostate, and brain health

最先进的临床人工智能解决方案，用于肺部、前列腺和大脑健康

DeepHealth will also showcase its latest clinical results and feature updates to its broader population health portfolio. DeepHealth’s clinical AI solutions include comprehensive, end-to-end AI-powered solutions for clinical diagnostics and high-volume screening in lung, breast, and prostate health, along with AI-driven innovations for brain health.

DeepHealth 还将展示其最新的临床结果，并介绍其更广泛的人口健康管理产品组合的功能更新。DeepHealth 的临床 AI 解决方案包括针对肺部、乳腺和前列腺健康的全面端到端人工智能诊断和高通量筛查解决方案，以及针对脑健康的 AI 驱动创新。

DeepHealth’s solutions are powering screening programs for breast cancer in the US and lung cancer in Europe..

DeepHealth的解决方案正在为美国的乳腺癌和欧洲的肺癌筛查项目提供支持。

DeepHealth’s AI-powered Lung solution

DeepHealth的AI驱动肺部解决方案

is used to assist radiologists in the NHS England’s Lung Cancer Screening Program, one of the world’s largest lung cancer screening initiatives. Within this program, 76% of detected cancers were caught at earlier, more treatable stages, compared to only 29% historically (without AI).

用于协助英国国家医疗服务体系（NHS）英格兰的肺癌筛查计划，这是全球规模最大的肺癌筛查计划之一。在此计划中，76%的检测到的癌症是在更早期、更可治疗的阶段发现的，而历史上（没有人工智能的情况下）这一比例仅为29%。

The solution provides AI-powered nodule detection, reporting, and patient management for enhanced efficiency and accuracy in lung cancer diagnosis by automatically detecting and segmenting lung nodules, enabling radiologists to interpret lung CT scans more confidently and, according to a recent study, up to 42% faster..

该解决方案提供人工智能驱动的结节检测、报告和患者管理，通过自动检测和分割肺结节，提高肺癌诊断的效率和准确性，使放射科医生能够更自信地解读肺部CT扫描，根据最近的一项研究，速度可提升高达42%。

In prostate cancer, DeepHealth’s AI-powered Prostate solution

在前列腺癌中，DeepHealth的AI驱动的前列腺解决方案

supports high-volume population health screening programs, diagnostic interpretation, and biopsy planning enabled by automated prostate segmentation, standardized reporting, and integration with most fusion biopsy systems. The solution has been shown to enable a 97% diagnostic sensitivity, up from 92% for radiologists without AI support.

支持大规模人群健康筛查项目、诊断解读以及通过自动前列腺分割、标准化报告和与大多数融合活检系统集成实现的活检规划。该解决方案已被证明可将诊断敏感性提高到97%，而没有人工智能支持的放射科医生仅为92%。

and recent analyses revealed a 37% reduction in workflow time for MRI read.

最近的分析显示，MRI读取的工作流程时间减少了37%。

Elements of DeepHealth’s portfolio are already delivering meaningful impact for patients and healthcare providers around the world, with over 800 clinical sites and more than 3,000 radiologists leveraging its current RIS, PACS, and AI solutions to deliver better care.

DeepHealth 的产品组合已经在为世界各地的患者和医疗保健提供者带来有意义的影响，目前已有 800 多个临床站点和 3,000 多名放射科医生利用其现有的 RIS、PACS 和 AI 解决方案来提供更好的护理。

At ECR 2025, DeepHealth’s portfolio of solutions

在ECR 2025上，DeepHealth的解决方案组合

Booth no. 507, X5

展位号：507，X5

About RadNet, Inc.

关于RadNet公司

RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas.

RadNet, Inc. 是美国基于网点数量和年度影像收入的领先的全国性独立固定场所诊断成像服务提供商。RadNet 拥有和/或运营一个由 399 家门诊影像中心组成的网络。RadNet 的市场包括亚利桑那州、加利福尼亚州、特拉华州、佛罗里达州、马里兰州、新泽西州、纽约州和德克萨斯州。

In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees.

此外，RadNet 还提供以 DeepHealth 品牌销售的放射学信息技术和人工智能解决方案、远程放射学专业服务以及其他相关产品和服务，服务于诊断影像行业的客户。RadNet 与附属的放射科医生一起，包括全职和按日计薪的员工及技术人员在内，共有超过 10,000 名员工。

For more information, visit .

欲了解更多信息，请访问。

www.radnet.com

About DeepHealth

关于DeepHealth

DeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet's Digital Health division. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (i.e., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth and Kheiron breast AI and Quantib prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health.

DeepHealth 是 RadNet, Inc.（纳斯达克股票代码：RDNT）的全资子公司，作为 RadNet 数字健康部门所有公司的伞形品牌。DeepHealth 提供由人工智能驱动的健康信息学，旨在通过影像技术推动护理领域的突破。基于其整合并重新命名的公司优势（例如，eRAD 放射信息与图像管理系统及影像存档和通信系统、Aidence 肺部 AI、DeepHealth 和 Kheiron 乳腺 AI 以及 Quantib 前列腺和脑部 AI），DeepHealth 利用先进的人工智能提升运营效率，并改善肺部、乳腺、前列腺和脑部健康的临床结果。

At the heart of DeepHealth’s portfolio is a cloud-native operating system - DeepHealth OS - that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs.

DeepHealth 产品组合的核心是一个云原生操作系统 —— DeepHealth OS，它统一了临床和操作工作流程中的数据，并为放射学领域的每个人个性化了 AI 驱动的工作空间。全球数百个影像中心和放射科部门的数千名放射科医生使用 DeepHealth 解决方案，以实现更早、更可靠和更高效的疾病检测，包括在大规模癌症筛查项目中。

DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. .

DeepHealth 的以人为本、直观的技术旨在突破医疗保健领域的可能性界限。

https://deephealth.com/

Forward Looking Statement

前瞻性声明

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, CARPL.ai, TeraRecon, and DeepHealth’s informatics, hardware and software product portfolios and the collaboration’s impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends.

本新闻稿包含1995年《美国私人证券诉讼改革法案》安全港条款所指的“前瞻性声明”。前瞻性声明包括关于RadNet、CARPL.ai、TeraRecon和DeepHealth的信息学、硬件和软件产品组合能力的声明，以及此次合作对放射学实践和医疗工作流程的影响，这些声明表达了我们对未来业务、未来计划和战略、预测以及预期的未来状况、事件和趋势的当前信念、期望和假设。

Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods..

前瞻性陈述通常可以通过以下词语来识别：“预期”、“打算”、“计划”、“目标”、“寻求”、“相信”、“预计”、“估计”、“期望”、“策略”、“未来”、“可能”、“应该”、“将”以及类似的指向未来时期的表述。

Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.

前瞻性陈述既不是历史事实，也不是对未来业绩的保证。由于前瞻性陈述与未来有关，因此它们本质上受到难以预测的不确定性、风险和环境变化的影响，其中许多因素是我们无法控制的。

Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements..

我们的实际结果和财务状况可能与前瞻性陈述中所表明的有重大差异。因此，您不应过分依赖这些前瞻性陈述中的任何一项。

For media inquiries, reach out to:

媒体咨询请联系：

Communications Director

通讯总监

Phone: +31 614 440971

电话：+31 614 440971

Email: andra.axente@deephealth.com

电子邮件：andra.axente@deephealth.com

Executive Vice President and Chief Financial Officer

执行副总裁兼首席财务官

310-445-2800

_______________________________

Not all products are regulatory cleared for use in all markets. Regulatory clearance varies by region and product. Please refer to www.deephealth.com or contact our regulatory affairs team for more information on the specific clearances applicable in your market.

并非所有产品都在所有市场获得监管批准使用。监管批准因地区和产品而异。有关适用于您市场的具体批准信息，请访问 www.deephealth.com 或联系我们的监管事务团队。

SmartMammo Dx + Assure used in a safeguard review process improved cancer detection rate by 21% in a study of over 575,000 patients, showing the same benefits across racial subgroups and patients with different breast densities. Data on file.

在一项针对超过 575,000 名患者的研究中，SmartMammo Dx + Assure 在保护性审查流程中的应用使癌症检出率提高了 21%，并且在不同种族亚组和不同乳腺密度的患者中均显示出相同的益处。数据存档。

并非所有产品都在所有市场获得监管批准。监管批准因地区和产品而异。有关适用于您市场的具体批准信息，请访问 www.deephealth.com 或联系我们的监管事务团队。

DeepHealth’s lung solution (Veye Lung Nodules in Europe) is manufactured for DeepHealth by Aidence B.V.

DeepHealth的肺部解决方案（在欧洲为Veye Lung Nodules）由Aidence B.V.为DeepHealth制造。

UK Department of Health and Social Care.

英国卫生和社会关怀部。

New lung cancer screening roll out to detect cancer sooner

推出新的肺癌筛查以更早检测癌症

Hempel HL et al. Higher agreement between readers with deep learning CAD for reporting pulmonary nodules on CT. Eur J Radiol Open. 2022;9:100435. doi: 10.1016/j.ejro.2022.100435.

Hempel HL 等。使用深度学习CAD报告CT上肺结节时，读者之间的一致性更高。《欧洲放射学开放期刊》。2022年；9：100435。doi: 10.1016/j.ejro.2022.100435。

DeepHealth’s prostate solution is manufactured as Quantib® Prostate for DeepHealth by Quantib B.V.

DeepHealth的前列腺解决方案由Quantib B.V.为DeepHealth生产，产品名为Quantib® Prostate。

Günzel et al., 2024.

冈泽尔等，2024。